Opsona Therapeutics, an Irish biotechnology company focused on novel therapeutic and preventative approaches to autoimmune and inflammatory diseases, has entered into a vaccine adjuvant research collaboration with Australia's CSL.
Under the terms of the agreement, Opsona will receive undisclosed upfront payments in return for the use of its OpsoVac technology. The agent, licensed from Trinity College, Dublin, inhibits T-regulatory cells to enhance anti-tumor immunity, according to the firms.
The "inhibition of T-regulatory cells is a promising approach to enhancing the effectiveness of both cancer immunotherapeutics and vaccines against chronic infectious diseases, such as hepatitis and influenza," added Andrew Cuthbertson, chief scientific officer of CSL.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2025 | Headless Content Management with Blaze